Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders
Contacts
FOR MORE INFORMATION, PLEASE CONTACT:
Investor Relations
Linda Kisa, CPA, CA
Email: lkisa@crescitatx.com
Crescita Therapeutics Inc. (TSX:CTX and OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company, today announced the voting results from its Annual General and Special Meeting of Shareholders held at its corporate headquarters in Laval, Quebec on June 20, 2023. The detailed results of the votes received by proxy are as follows:
Election of Directors
Director Nominees |
NUMBER OF SHARES |
PERCENTAGE OF VOTES CAST |
||
FOR |
WITHHELD |
FOR |
WITHHELD |
|
Daniel N. Chicoine |
4,113,511 |
91,743 |
97.8% |
2.2% |
Anthony E. Dobranowski |
3,549,815 |
655,439 |
84.4% |
15.6% |
John C. London |
3,550,494 |
654,760 |
84.4% |
15.6% |
Deborah Shannon-Trudeau |
4,115,644 |
89,610 |
97.9% |
2.1% |
Serge Verreault |
3,550,534 |
654,720 |
84.4% |
15.6% |
Appointment of External Auditors
Outcome |
NUMBER OF SHARES |
PERCENTAGE OF VOTES CAST |
||
FOR |
WITHHELD |
FOR |
WITHHELD |
|
Ernst & Young LLP reappointed |
4,965,906 |
47,466 |
99.1% |
0.9% |
Consideration of a Special Resolution Approving a Change of the Municipality of Crescita’s Registered Office
Outcome |
NUMBER OF SHARES |
PERCENTAGE OF VOTES CAST |
||
FOR |
AGAINST |
FOR |
AGAINST |
|
Change of municipality approved |
4,181,460 |
23,794 |
99.4% |
0.6% |
About Crescita Therapeutics Inc.
Crescita (TSX:CTX and OTC US: CRRTF) is a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house R&D and manufacturing capabilities. The Company offers a portfolio of high-quality, science-based non-prescription skincare products and early to commercial stage prescription products. We also own multiple proprietary transdermal delivery platforms that support the development of patented formulations to facilitate the delivery of active ingredients into or through the skin. For further details, visit www.crescitatherapeutics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230621953997/en/
Related news for (CRRTF)
- Crescita Reports Second Quarter 2024 Results
- Crescita Secures Contract Manufacturing Revenue of $US10 Million Over 4 Years
- Leading Canadian Healthcare Services Provider Selects Crescita as Exclusive Manufacturing Partner under 5-Year Agreement
- Crescita Expands Medical Aesthetic Portfolio with MicronJetTM600 The World’s Smallest Intradermal Delivery Device
- Crescita Completes Acquisition of Strategic Assets of Occy Laboratory